Pathology & Laboratory Medicine

You are here

Dr. Mark Rubin Receives 3-Year R01 Award

Please join us in congratulating Dr. Mark Rubin on receiving a 3-year R01 award for $500k.

Along with his collaborator at Yale, Dr. Mark Gerstein, Dr. Rubin will develop approaches to identify non-coding mutations that are important for prostate cancer. 

Mark A Rubin, MD Director, Institute for Precision Medicine

Cancer cells have many non-coding mutations.  The significance of these potential important mutations to disease is unknown and has been largely unexplored.  Dr. Rubin will develop approaches to identify non-coding mutations that likely contribute to prostate cancer and determine how these mutations impact the expression of genes required for this disease.

Congratulations Dr. Rubin!

Weill Cornell Medicine Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464 Fax: (212) 746-8192